{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T06:53:24Z","timestamp":1780988004782,"version":"3.54.1"},"reference-count":61,"publisher":"Informa UK Limited","issue":"10","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Hematology"],"published-print":{"date-parts":[[2024,10,2]]},"DOI":"10.1080\/17474086.2024.2389993","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T09:35:15Z","timestamp":1723023315000},"page":"651-659","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Evaluating pirtobrutinib for the treatment of relapsed or refractory mantle cell lymphoma"],"prefix":"10.1080","volume":"17","author":[{"given":"Jacqueline F.","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Medicine, NYU Langone Health, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yucai","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,8,8]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2202672"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2020.05.002"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17419"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013326"},{"key":"e_1_3_5_7_1","unstructured":"U.S. Food and Drug Administration. FDA approves brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma [Internet]. 2020. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-brexucabtagene-autoleucel-relapsed-or-refractory-mantle-cell-lymphoma"},{"key":"e_1_3_5_8_1","unstructured":"U.S. Food and Drug Administration. FDA grants accelerated approval to pirtobrutinib for relapsed or refractory mantle cell lymphoma [Internet]. 2023. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-pirtobrutinib-relapsed-or-refractory-mantle-cell-lymphoma"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13020291"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0779-z"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22147641"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.2174\/0109298673251030231004052822"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-635326"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-168152"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33108-2"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0575-9"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3703"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014162"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020004074"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020240"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400029"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1457148"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006783"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-10-673145"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15567"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv111"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18519"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02370"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01797"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02214"},{"key":"e_1_3_5_33_1","unstructured":"U.S. Food and Drug Administration. FDA grants accelerated approval to pirtobrutinib for chronic lymphocytic leukemia and small lymphocytic lymphoma [Internet]. 2023. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-pirtobrutinib-chronic-lymphocytic-leukemia-and-small-lymphocytic"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0670"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-187405"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157777"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00889-8"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-178118"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-175035"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.48"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018674"},{"key":"e_1_3_5_42_1","unstructured":"U.S. Food and Drug Administration. FDA jaypirca full prescribing information [Internet]. 2023. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/216059s001lbl.pdf"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2114110"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-180143"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00224-5"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00562"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.7514"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(23)01372-1"},{"key":"e_1_3_5_49_1","unstructured":"Wang ML Shah NN Jurczak W et al. Pirtobrutinib in covalent BTK-Inhibitor pre-treated mantle cell lymphoma: updated results and subgroup analysis from the phase 1\/2 BRUIN study with 2 years of survival follow-up [Internet]. 2023. Available from: https:\/\/assets.ctfassets.net\/mpejy6umgthp\/1GsuSYBkWKpHMAIZ8OMyS2\/9f9e2718ab41f5c13536b185aa8b6197\/MCL-155-Poster.pdf"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-181627"},{"key":"e_1_3_5_51_1","unstructured":"Cohen JB Shah NN Jurczak W et al. Pirtobrutinib in Relapsed\/Refractory (R\/R) mantle cell lymphoma (MCL) patients with prior cBtki: updated safety and efficacy including High-risk subgroup analyses from the phase 1\/2 BRUIN study [Internet]. Eli Lilly; 2023. Available from: https:\/\/assets.ctfassets.net\/mpejy6umgthp\/5XlPfb3vNKl7NT0QKt6I0C\/cde25f7b11f5ec4e7a13e0bb8265f20b\/ASH23_COHEN_981_PRES_07DEC.pdf"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-173287"},{"key":"e_1_3_5_53_1","unstructured":"Song Y Liu Y Huang H et al. Pirtobrutinib a non-covalent (reversible) BTK inhibitor in mantle cell lymphoma patients previously treated with a covalent BTK inhibitor: results from a China phase 2 study [internet]. Eli Lilly; 2023. Available from: https:\/\/assets.ctfassets.net\/mpejy6umgthp\/2N6QNnsv0u0uw8BBWrLegg\/993c5cf90c11fa7ec633af43e29c6175\/ASH2023_ZHU_3636_PSTR.pdf"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0976"},{"key":"e_1_3_5_55_1","unstructured":"ClinicalTrials.gov. Study of BTK inhibitor LOXO-305 versus approved BTK inhibitor drugs in patients with mantle cell lymphoma (MCL) (BRUIN-MCL-321). U.S. National Library of Medicine; 2023. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04662255"},{"key":"e_1_3_5_56_1","unstructured":"ClinicalTrials.gov. Phase II study of Pirtobrutinib rituximab (PR) in Previously untreated low and intermediate risk MCL (mantle cell lymphoma) patients [Internet]. U.S. National Library of Medicine; 2026. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06263491"},{"key":"e_1_3_5_57_1","unstructured":"ClinicalTrials.gov. Phase II study of pirtobrutinib with venetoclax in relapsed-refractory MCL (mantle cell lymphoma) patients [internet]. U.S. National Library of Medicine; 2024. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05529069"},{"key":"e_1_3_5_58_1","unstructured":"ClinicalTrials.gov. Glofitamab with pirtobrutinib for relapsed or refractory mantle cell lymphoma [internet]. U.S. National Library of Medicine; 2024. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06252675"},{"key":"e_1_3_5_59_1","unstructured":"ClinicalTrials.gov. A phase 2 trial of GlOfitamab anD pIrtobrutinib in mantle cell lymphoma patients with prior BTK inhibitor exposure. (GOlDiLOX) [Internet]. U.S. National Library of Medicine; 2024. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05833763"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(23)01494-5"},{"key":"e_1_3_5_61_1","unstructured":"Muehlenbein CE Coombs CC Shah NN et al. Long-term safety with \u226512 months of pirtobrutinib in Relapsed\/Refractory B-Cell malignancies [Internet]. 2023. Available from: https:\/\/assets.ctfassets.net\/mpejy6umgthp\/6KPYmPMDr9RHDYIAjWVZY2\/8284fc1583e2adc93ee1a2e7732d73ba\/CT-166-Poster.pdf"},{"key":"e_1_3_5_62_1","unstructured":"European Medicines Agency. Jaypirca. European Medicines Agency [Internet]. 2023. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/jaypirca"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-177741"}],"container-title":["Expert Review of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17474086.2024.2389993","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T01:26:11Z","timestamp":1727227571000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17474086.2024.2389993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,8]]},"references-count":61,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10,2]]}},"alternative-id":["10.1080\/17474086.2024.2389993"],"URL":"https:\/\/doi.org\/10.1080\/17474086.2024.2389993","relation":{},"ISSN":["1747-4086","1747-4094"],"issn-type":[{"value":"1747-4086","type":"print"},{"value":"1747-4094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,8]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-01-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}